Table 5.

Strategy-immune checkpoint inhibitors and tyrosine kinase inhibitors combination therapy.

Intervention	Strategy	Date (last updated)	Status	Patient population	Phase	Study design	ClinicalTrials.gov identifier
Ipilimumab + Imatinib mesylate	CTLA-4 inhibitor, Tyrosine kinase inhibitor	30 November 2015	Recruiting	Advanced cancer	I	Combination therapy of Ipilimumab with Dose Escalation of Imatinib mesylate	NCT01738139
Pembrolizumab + ACP-196	PD-1 inhibitor, Bruton tyrosine kinase inhibitor	30 November 2015	Active but not recruiting	Advanced or metastatic pancreatic cancer	II	Arm1- ACP-196 alone Arm2- ACP-196 + Pembrolizumab	NCT02362048
Pembrolizumab + PLX3397	PD-1 inhibitor, Tyrosine kinase inhibitor	9 October 2015	Recruiting	Advanced solid tumors including pancreatic cancer	I	Arm- PLX3397 + pembrolizumab combination therapy	NCT02452424
MEDI4736 + Ibrutinib mesylate	PD-L1 inhibitor, Tyrosine kinase inhibitor	4 September 2015	Recruiting	Refractory or relapsed solid tumors	Ib/II	Phase Ib- MEDI4736+ Ibrutinib to determine the recommended phase II dose level Phase II- MEDI4736+ Ibrutinib at recommended phase II dose level	NCT02403271